Follow The Short Interest: Does Xenon Pharmaceuticals Incorporated (NASDAQ:XENE) Have Gas After Even More Sellers Involved?

November 21, 2016 - By Winifred Garcia   ·   0 Comments

Follow The Short Interest: Does Xenon Pharmaceuticals Incorporated (NASDAQ:XENE) Have Gas After Even More Sellers Involved?

The stock of Xenon Pharmaceuticals Incorporated (NASDAQ:XENE) registered an increase of 6.46% in short interest. XENE’s total short interest was 31,300 shares in November as published by FINRA. Its up 6.46% from 29,400 shares, reported previously. With 60,000 shares average volume, it will take short sellers 1 days to cover their XENE’s short positions. The short interest to Xenon Pharmaceuticals Incorporated’s float is 0.35%. About 6,807 shares traded hands. Xenon Pharmaceuticals Inc (NASDAQ:XENE) has risen 17.86% since April 19, 2016 and is uptrending. It has outperformed by 14.00% the S&P500.

Xenon Pharmaceuticals Inc. is a biopharmaceutical firm discovering and developing a pipeline of differentiated therapeutics for orphan indications. The company has a market cap of $156.30 million. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). It currently has negative earnings. Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) Ratings Coverage

Out of 4 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Xenon Pharmaceuticals has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Zacks upgraded Xenon Pharmaceuticals Inc (NASDAQ:XENE) on Tuesday, August 11 to “Sell” rating. Guggenheim initiated the shares of XENE in a report on Monday, September 26 with “Buy” rating. The stock of Xenon Pharmaceuticals Inc (NASDAQ:XENE) earned “Sell” rating by Zacks on Wednesday, September 2. The rating was maintained by Jefferies with “Buy” on Wednesday, March 9. The company was reinitiated on Friday, October 30 by Jefferies. Stifel Nicolaus initiated the stock with “Buy” rating in Friday, October 21 report. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, August 11. Zacks upgraded the shares of XENE in a report on Wednesday, August 19 to “Sell” rating.

XENE Company Profile

Xenon Pharmaceuticals Inc. (Xenon), incorporated on April 17, 2000, is a biopharmaceutical firm discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Firm has built a core platform, Extreme Genetics, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. The Firm has an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. The Company’s development pipeline includes Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.

More recent Xenon Pharmaceuticals Inc (NASDAQ:XENE) news were published by: Marketwatch.com which released: “Xenon Pharmaceuticals started at buy with $18 stock price target at Stifel …” on November 02, 2014. Also Quotes.Wsj.com published the news titled: “News Xenon Pharmaceuticals Inc.XENE” on October 10, 2014. Globenewswire.com‘s news article titled: “Xenon Pharmaceuticals Achieves Milestone in Genentech Collaboration to …” with publication date: September 21, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>